MabCure Establishes Research Facilities on the Campus of Hasselt University

MabCure, N.V. (�MabCure�) a wholly owned subsidiary of MabCure Inc.(OTC BB:MBCI.OB) and LifeTechLimburg are pleased to announce the establishment of MabCure�s global research facilities on the research campus of Hasselt University where it will collaborate with the Biomedical Research Institute (�BIOMED�).

�MabCure aims to become a major player in the global cancer diagnostics field and we are privileged to be able to collaborate with BIOMED, which is well-known for its research activities in the field of chronic diseases including multiple sclerosis,� said Dr. Amnon Gonenne, MabCure�s President and CEO.

BIOMED Director, Professor Piet Stinissen, said, �We are privileged that MabCure chose to establish their research facilities at our institute. We are very impressed with their technology and their team and have full faith in their ability to make an impact on the field of cancer. We look forward to working together on joint projects for our mutual benefit.�

MabCure and BIOMED have already voiced their intentions to cooperate on various joint projects, deploying MabCure�s technology for the generation of novel antibodies for various applications in the autoimmune disease field.

Research activities at MabCure will be led by Dr. Elisha Orr, MabCure�s Chief Scientific Officer, an expert in molecular biology and immunology and the developer of MabCure�s technology and novel antibodies.

The decision of MabCure to relocate to Limburg can partially be attributed to the support of LifeTechLimburg, your helping hand for life sciences and medical technology. �Being proceeded by the company Apitope only a few months ago, the relocation of MabCure once again demonstrates that Limburg holds important assets to attract foreign life science companies,� said Dr. Debora Dumont, Manager of LifeTechLimburg.

The start-up of MabCure will be announced at BIOMEDICA, the key life sciences event in the Euregion Meuse-Rhine. Proceeded by two successful editions, BIOMEDICA 2009 is organised on 1-2 April in the Palais des Congr�s in Li�ge, Belgium. BIOMEDICA is organised by the partnering organisations in the Euregion, including LifeTechLimburg. Marc Vandeput, deputy of economics affairs, said, �The province of Limburg acknowledges life sciences as a spearhead sector and financially supports BIOMEDICA via �Limburg Strong Brand.� This allows a strong visibility of the Limburg life sciences sector at this event.�

About MabCure

MabCure is a biotechnology company whose vision is to change the perception of cancer as being a largely incurable disease. MabCure owns proprietary technology for the creation of unique and highly specific monoclonal antibodies (Mabs) which will be developed as diagnostic tools, imaging agents and drugs to treat lethal cancers. MabCure initial goal is to develop its novel Mabs as diagnostic tools for the detection of Ovarian and Prostate cancers at an early stage, when these diseases are still localized and highly curable. For further information visit the Company�s website www.mabcure.com.

About BIOMED

The Biomedical Research Institute (BIOMED) is a life sciences research institute of Hasselt University with a staff of 80 researchers, clinicians and technicians. The key research domains are focused on neuro-inflammatory and autoimmune diseases (multiple sclerosis and rheumatoid arthritis) and development of biosensors.

www.biomed.uhasselt.be

About LifeTechLimburg

LifeTechLimburg, your helping hand for life sciences and medical technology, is the driving force behind the enforcement of the life sciences sector in the provincie of Limburg. LifeTechLimburg aims to stimulate innovation within existing life sciences companies and to create novel and attrack foreign companies with R&D activities in the field of biomedical life sciences.

www.lifetechlimburg.be

This news release contains �forward-looking statements�. Statements in this news release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the change of business focus of the management of the Company or the University and the inability of the Company or the University to pursue its current objectives. These forward-looking statements are made as of the date of this news release and the Company or the University assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements.

MabCure (CE) (USOTC:MBCI)
Historical Stock Chart
From Jun 2024 to Jul 2024